Advertisement

Picture BIO Deutschland Biotech Investors Day BID 2019 Würzburg 600x60px
Document › Details

AB Science S.A.. (11/14/13). "Press Release: Issue of New Shares". Paris.

Region Region France
Organisations Organisation AB Science S.A. (NYSE Euronext - FR0010557264 - AB)
  Group AB Science (Group)
  Organisation 2 Société Générale S.A.
  Group Société Générale (Group)
Products Product kinase inhibitor
  Product 2 investment banking
Index term Index term AB Science–SEVERAL: investment, 201311 capital increase €4.98m 256k new shares €19.47/share
     


AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), has decided, according to PACEO® set up with Societe Generale on May 3rd 2012, to proceed with the issue of:

- 256,000 new shares
- for the price of €19.47 per share


The issue price of the new shares showed a 5% discount compared to the weighted average price over the last three trading sessions.

Following this transaction, the number of AB Science shares outstanding will increase from 32,339,187 shares to 32,595,187 shares, the issue of 256,000 new shares representing 0.77% of the total shares after the transaction.

The new shares are freely transferable and immediately assimilated with the existing ordinary shares, which are listed on Euronext Paris.


A propos d'AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases, and central nervous system diseases), in both human and veterinary medicines. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine in Europe and in the USA, and is pursuing ten on-going phase 3 studies in human medicine in GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, Alzheimer's disease, progressive forms of multiple sclerosis, and in Amyotrophic Lateral Sclerosis. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science website: www.ab-science.com.

   
Record changed: 2016-01-10

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for AB Science (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px




» top